About this trial
The goal of this randomised controlled trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.
The main question it aims to answer is if Vitamin D supplementation, administered as oral vitamin D₃ at a dose of 2,000 IU once daily, from the time of recruitment to the time of delivery, reduces the incidence of preeclampsia, eclampsia and HELLP syndrome in pregnant women attending ANC at St. Mary's Hospital, Lacor, such incidence being monitored up to six (6) weeks after delivery.
Researchers will compare the effect of oral 2.000 IU vitamin D daily (intervention group) vs. oral placebo daily (control group) on the prevalence of adverse maternal and foetal outcomes.
Eligibility criteria
Qualifiers
with a viable intrauterine pregnancy,
at gestational age at recruitment between 13 weeks 0 days and 27 weeks 6 days, and
who consented to participate in the study.
Disqualifiers
women already on Vitamin D treatment prescribed by a physician.
Trial design
Treatments tested in this trial
- oral 2.000 IU vitamin D3 (cholecalciferol) daily, in addition to routine ANC supplementations
- Placebo
Treatment groups
Locations
Sponsors and collaborators
St Mary's Hospital, Lacor
Lead sponsor
University of Naples
Collaborator